Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH) Frontiers in Oncology. 2021 Nov 19
Fragment- and Structure-based Drug Discovery for Developing Therapeutic Agents Targeting the DNA Damage Response Prog Biophys Mol Biol, Aug 2021
Crystal Structure and Activity Studies of the C11 Cysteine Peptidase from Parabacteroides merdae in the Human Gut Microbiome J Biol Chem. 2016
PNT1 Is a C11 Cysteine Peptidase Essential for Replication of the Trypanosome Kinetoplast. J Biol Chem. 2016
Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket. J Struct Biol. 2015
Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. Proc Nat Acad of Sci. 2015.
The signaling phospholipid PIP3 binds SF-1 creating a new interaction surface at the entrance of the ligand binding pocket. Proc Nat Acad of Sci. 2014.
Crystal structure of a putative quorum sensing-regulated protein (PA3611) from the Pseudomonas-specific DUF4146 family. Proteins 2014.
Structure and function of the DUF2233 domain in bacteria and in the human mannose 6-phosphate uncovering enzyme. J Biol Chem. 2013.
Structure and function of a novel LD-carboxypeptidase a involved in peptidoglycan recycling. J Bacteriol. 2013
Application of DEN refinement and automated model building to a difficult case of molecular-replacement phasing: the structure of a putative succinyl-diaminopimelate desuccinylase from Corynebacterium glutamicum. Acta Crystallogr D Biol Crystallogr. 2012.
Improved molecular replacement by density- and energy-guided protein structure optimization. Nature 2011.
Structure and function of the first full-length murein peptide ligase (Mpl) cell wall recycling protein PLoS One 2011.
Structure of the First Eubacterial Mre11 Nuclease Reveals Novel Features that May Discriminate Substrates During DNA Repair. J Mol Biol. 2011.
June 2021: Accelero Biostructures Selected for Company Presentation and Inclusion in the NIH Innovation Zone at BIO 2021
December 2020: XPose Therapeutics and Accelero Biostructures announce Joint Research Collaboration for the Discovery and Development of Novel Cancer Therapies
July 2020: Accelero Biostructures Partners with Mid-Atlantic BioTherapeutics to develop Pan-Coronavirus Inhibitors; Receives NIH Funding to Support the Research
May 2019: Accelero Biostructures, Inc. has received additional non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase II program
March 2019: Accelero Biostructures, Inc. expedites structure determinations for groundbreaking research expanding the DNA alphabet from 4 to 8 building blocks
Sept. 2016: Accelero Biostructures, Inc. has received non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase I program
January 2015: Accelero Biostructures, Inc. is founded with help from the University of California’s QB3 program
